Register
FDA approves blinatumomab for MRD-positive acute lymphoblastic leukemia |
Journal Updates
eMediNexus Coverage from: 
FDA approves blinatumomab for MRD-positive acute lymphoblastic leukemia
eMediNexus,  30 March 2018
remove_red_eye 971 Views
#Hematology #Nursing #Oncology #Pathology and Lab Medicine

0 Read Comments                

The US FDA has expanded the approval of blinatumomab (Blincyto) to include the treatment of B-cell precursor acute lymphoblastic leukemia (ALL), for patients in remission who still have minimal residual disease (MRD).
To continue reading this article
Or

Continue reading your article with a Emedinexus account..
Free Membership!